BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tada H, Satoh S, Iinuma M, Shimoda N, Murakami M, Hayase Y, Kato T, Suzuki T. Chronopharmacokinetics of tacrolimus in kidney transplant recipients: occurrence of acute rejection. J Clin Pharmacol. 2003;43:859-865. [PMID: 12953343 DOI: 10.1177/0091270003254797] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Knoop C, Thiry P, Saint-Marcoux F, Rousseau A, Marquet P, Estenne M. Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions. Am J Transplant 2005;5:1477-82. [PMID: 15888057 DOI: 10.1111/j.1600-6143.2005.00870.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 1.8] [Reference Citation Analysis]
2 Medina‐aymerich L, González‐ramírez R, García‐roca P, Reyes H, Hernández AM, Medeiros M, Castañeda‐hernández G. Limited sampling strategy to predict the area under the curve of tacrolimus in Mexican renal transplant pediatric patients receiving Prograf ® or non‐innovator formulations. Pediatr Transplant 2019;23. [DOI: 10.1111/petr.13595] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Satoh S, Tada H, Murakami M, Tsuchiya N, Li Z, Numakura K, Saito M, Inoue T, Miura M, Hayase Y, Suzuki T, Habuchi T. Circadian pharmacokinetics of mycophenolic Acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients. Transplantation 2006;82:486-93. [PMID: 16926592 DOI: 10.1097/01.tp.0000231874.53240.ba] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.0] [Reference Citation Analysis]
4 Numakura K, Satoh S, Tsuchiya N, Horikawa Y, Inoue T, Kakinuma H, Matsuura S, Saito M, Tada H, Suzuki T, Habuchi T. Clinical and Genetic Risk Factors for Posttransplant Diabetes Mellitus in Adult Renal Transplant Recipients Treated with Tacrolimus. Transplantation 2005;80:1419-24. [DOI: 10.1097/01.tp.0000181142.82649.e3] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 3.9] [Reference Citation Analysis]
5 Barraclough KA, Staatz CE, Johnson DW, Lee KJ, Mcwhinney BC, Ungerer JP, Hawley CM, Campbell SB, Leary DR, Isbel NM. Kidney transplant outcomes are related to tacrolimus, mycophenolic acid and prednisolone exposure in the first week: Kidney transplant outcomes are related to tacrolimus, MPA and prednisolone exposure. Transplant International 2012;25:1182-93. [DOI: 10.1111/j.1432-2277.2012.01553.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
6 Press RR, Ploeger BA, Hartigh JD, Straaten TVD, Pelt JV, Danhof M, Fijter JWD, Guchelaar H. Explaining Variability in Tacrolimus Pharmacokinetics to Optimize Early Exposure in Adult Kidney Transplant Recipients. Therapeutic Drug Monitoring 2009;31:187-97. [DOI: 10.1097/ftd.0b013e31819c3d6d] [Cited by in Crossref: 96] [Cited by in F6Publishing: 41] [Article Influence: 7.4] [Reference Citation Analysis]
7 Momper JD, Ridenour TA, Schonder KS, Shapiro R, Humar A, Venkataramanan R. The Impact of Conversion From Prograf to Generic Tacrolimus in Liver and Kidney Transplant Recipients With Stable Graft Function: Generic Substitution of Tacrolimus in Transplant. American Journal of Transplantation 2011;11:1861-7. [DOI: 10.1111/j.1600-6143.2011.03615.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 44] [Article Influence: 5.2] [Reference Citation Analysis]
8 Curtis JJ, Jones P, Barbeito R. Large within-day variation in cyclosporine absorption: circadian variation or food effect? Clin J Am Soc Nephrol 2006;1:462-6. [PMID: 17699246 DOI: 10.2215/CJN.01531005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
9 Niioka T, Satoh S, Kagaya H, Numakura K, Inoue T, Saito M, Narita S, Tsuchiya N, Habuchi T, Miura M. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation. Transplantation 2012;94:1013-9. [PMID: 23073468 DOI: 10.1097/TP.0b013e31826bc400] [Cited by in Crossref: 43] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
10 Shuker N, van Gelder T, Hesselink DA. Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management. Transplant Rev (Orlando). 2015;29:78-84. [PMID: 25687818 DOI: 10.1016/j.trre.2015.01.002] [Cited by in Crossref: 104] [Cited by in F6Publishing: 92] [Article Influence: 14.9] [Reference Citation Analysis]
11 Hon YY, Chamberlain CE, Kleiner DE, Ring MS, Hale DA, Kirk AD, Mannon RB. Evaluation of tacrolimus abbreviated area-under-the-curve monitoring in renal transplant patients who are potentially at risk for adverse events. Clin Transplant 2010;24:557-63. [PMID: 19925470 DOI: 10.1111/j.1399-0012.2009.01143.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
12 Satoh S, Kagaya H, Saito M, Inoue T, Miura M, Inoue K, Numakura K, Tsuchiya N, Tada H, Suzuki T, Habuchi T. Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients. Br J Clin Pharmacol 2008;66:207-14. [PMID: 18429967 DOI: 10.1111/j.1365-2125.2008.03188.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
13 Scholten EM, Rowshani AT, Cremers S, Bemelman FJ, Eikmans M, van Kan E, Mallat MJ, Florquin S, Surachno J, ten Berge IJ, Bajema IM, de Fijter JW. Untreated rejection in 6-month protocol biopsies is not associated with fibrosis in serial biopsies or with loss of graft function. J Am Soc Nephrol 2006;17:2622-32. [PMID: 16899517 DOI: 10.1681/ASN.2006030227] [Cited by in Crossref: 53] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
14 Kuypers DRJ, Claes K, Evenepoel P, Maes B, Vanrenterghem Y. THE RATE OF GASTRIC EMPTYING DETERMINES THE TIMING BUT NOT THE EXTENT OF ORAL TACROLIMUS ABSORPTION: SIMULTANEOUS MEASUREMENT OF DRUG EXPOSURE AND GASTRIC EMPTYING BY CARBON-14-OCTANOIC ACID BREATH TEST IN STABLE RENAL ALLOGRAFT RECIPIENTS. Drug Metab Dispos 2004;32:1421-5. [DOI: 10.1124/dmd.104.001503] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
15 Kuypers DRJ. Immunosuppressive drug monitoring - what to use in clinical practice today to improve renal graft outcome. Transplant Int 2005;18:140-50. [DOI: 10.1111/j.1432-2277.2004.00041.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 3.2] [Reference Citation Analysis]
16 Baraldo M, Furlanut M. Chronopharmacokinetics of ciclosporin and tacrolimus. Clin Pharmacokinet 2006;45:775-88. [PMID: 16884317 DOI: 10.2165/00003088-200645080-00002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
17 Murakami T, Bodor E, Bodor N. Modulation of expression/function of intestinal P-glycoprotein under disease states. Expert Opinion on Drug Metabolism & Toxicology 2020;16:59-78. [DOI: 10.1080/17425255.2020.1701653] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
18 Udomkarnjananun S, Francke MI, De Winter BCM, Mulder MB, Baan CC, Metselaar HJ, den Hoed CM, Hesselink DA. Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology. Best Pract Res Clin Gastroenterol 2021;54-55:101756. [PMID: 34874840 DOI: 10.1016/j.bpg.2021.101756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Kuypers DR, Vanrenterghem Y. Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients. Clin Ther 2004;26:1834-44. [PMID: 15639695 DOI: 10.1016/j.clinthera.2004.11.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
20 Barraclough KA, Isbel NM, Kirkpatrick CM, Lee KJ, Taylor PJ, Johnson DW, Campbell SB, Leary DR, Staatz CE. Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients. Br J Clin Pharmacol 2011;71:207-23. [PMID: 21219401 DOI: 10.1111/j.1365-2125.2010.03815.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
21 Benkali K, Prémaud A, Picard N, Rérolle J, Toupance O, Hoizey G, Turcant A, Villemain F, Le Meur Y, Marquet P, Rousseau A. Tacrolimus Population Pharmacokinetic-Pharmacogenetic Analysis and Bayesian Estimation in Renal Transplant Recipients: . Clinical Pharmacokinetics 2009;48:805-16. [DOI: 10.2165/11318080-000000000-00000] [Cited by in Crossref: 104] [Cited by in F6Publishing: 96] [Article Influence: 8.0] [Reference Citation Analysis]
22 Greanya ED, Poulin E, Partovi N, Shapiro RJ, Al-khatib M, Ensom MHH. Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. American Journal of Health-System Pharmacy 2012;69:134-42. [DOI: 10.2146/ajhp110287] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
23 Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L, Hebral AL, Bellière J, Kamar N. High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation. World J Gastroenterol 2018; 24(16): 1795-1802 [PMID: 29713132 DOI: 10.3748/wjg.v24.i16.1795] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
24 Iwahori T, Takeuchi H, Matsuno N, Johjima Y, Konno O, Nakamura Y, Hama K, Uchiyama M, Ashizawa T, Okuyama K, Nagao T, Abudoshukur M, Hirano T, Oka K. Pharmacokinetic differences between morning and evening administration of cyclosporine and tacrolimus therapy. Transplant Proc 2005;37:1739-40. [PMID: 15919450 DOI: 10.1016/j.transproceed.2005.02.104] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
25 Park S, Felipe CR, Pinheiro-machado PG, Garcia R, Tedesco-silva H, Medina-pestana JO. Circadian and time-dependent variability in tacrolimus pharmacokinetics. Fundam Clin Pharmacol 2007;21:191-7. [DOI: 10.1111/j.1472-8206.2007.00468.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
26 Vadcharavivad S, Susomboon T, Kulabusaya B, Avihingsanon Y, Praditpornsilpa K, Townamchai N. Validation of a 2-Point Limited Sampling Strategy to Predict the Tacrolimus Area-Under-the-12-Hour-Curve in Kidney Transplant Recipients. Ther Drug Monit 2016;38:614-20. [PMID: 27328329 DOI: 10.1097/FTD.0000000000000317] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
27 Barraclough KA, Isbel NM, Johnson DW, Campbell SB, Staatz CE. Once- Versus Twice-Daily Tacrolimus: Are the Formulations Truly Equivalent? Drugs 2011;71:1561-77. [DOI: 10.2165/11593890-000000000-00000] [Cited by in Crossref: 71] [Cited by in F6Publishing: 61] [Article Influence: 6.5] [Reference Citation Analysis]
28 Gustavsen MT, Midtvedt K, Robertsen I, Woillard JB, Debord J, Klaasen RA, Vethe NT, Bergan S, Åsberg A. Fasting Status and Circadian Variation Must be Considered When Performing AUC-based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients. Clin Transl Sci 2020;13:1327-35. [PMID: 32652886 DOI: 10.1111/cts.12833] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
29 van Rongen A, Kervezee L, Brill M, van Meir H, den Hartigh J, Guchelaar HJ, Meijer JH, Burggraaf J, van Oosterhout F. Population Pharmacokinetic Model Characterizing 24-Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers. CPT Pharmacometrics Syst Pharmacol 2015;4:454-64. [PMID: 26380154 DOI: 10.1002/psp4.12007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
30 Fontova P, Colom H, Rigo-Bonnin R, van Merendonk LN, Vidal-Alabró A, Montero N, Melilli E, Meneghini M, Manonelles A, Cruzado JM, Torras J, Grinyó JM, Bestard O, Lloberas N. Influence of the Circadian Timing System on Tacrolimus Pharmacokinetics and Pharmacodynamics After Kidney Transplantation. Front Pharmacol 2021;12:636048. [PMID: 33815118 DOI: 10.3389/fphar.2021.636048] [Reference Citation Analysis]
31 Miura Y, Satoh S, Saito M, Numakura K, Inoue T, Obara T, Tsuruta H, Narita S, Horikawa Y, Tsuchiya N, Komatsuda A, Kagaya H, Miura M, Habuchi T. Factors increasing quantitative interstitial fibrosis from 0 hr to 1 year in living kidney transplant patients receiving tacrolimus. Transplantation 2011;91:78-85. [PMID: 21452412 DOI: 10.1097/tp.0b013e3181ff4f7f] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
32 Satoh S, Saito M, Inoue T, Kagaya H, Miura M, Inoue K, Komatsuda A, Tsuchiya N, Suzuki T, Habuchi T. CYP3A5 *1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients. Eur J Clin Pharmacol 2009;65:473-81. [PMID: 19125240 DOI: 10.1007/s00228-008-0606-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
33 Baraldo M. The influence of circadian rhythms on the kinetics of drugs in humans. Expert Opin Drug Metab Toxicol 2008;4:175-92. [PMID: 18248311 DOI: 10.1517/17425255.4.2.175] [Cited by in Crossref: 106] [Cited by in F6Publishing: 90] [Article Influence: 7.6] [Reference Citation Analysis]
34 Scholten EM, Cremers SC, Schoemaker RC, Rowshani AT, van Kan EJ, den Hartigh J, Paul LC, de Fijter JW. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int. 2005;67:2440-2447. [PMID: 15882290 DOI: 10.1111/j.1523-1755.2005.00352.x] [Cited by in Crossref: 121] [Cited by in F6Publishing: 107] [Article Influence: 7.1] [Reference Citation Analysis]